Recent Updates
Recently added Catalysts
INCR Negative Sentiment Score: 35/100

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary NEW YORK, TORONTO, and

Key Takeaway: InterCure Ltd. announced that a lawsuit was filed against it by minority shareholders of its subsidiary, Cannolam, due to ongoing management disputes. The lawsuit was submitted to the Tel Aviv-Jaffa District Court, and InterCure believes the claims are without valid legal basis. The company intends to evaluate all legal options available and is committed to vigorously defending its interests amidst this conflict.

Market Sentiment Analysis

POSITIVE FACTORS

  • InterCure believes the claims lack a valid legal basis.
  • The company is committed to defending its interests.
  • InterCure holds a strong position as a leading cannabis company.

CONCERNS & RISKS

  • A lawsuit has been filed against InterCure by minority shareholders.
  • The lawsuit arises from management disagreements within the subsidiary Cannolam.
  • The company's reputation might be impacted by ongoing legal conflicts.

Full Press Release Details

Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
YORK, TORONTO, and HERZLIYA, Israel - April 25, 2023 - InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR)
(dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North
America announces that on April 24, 2023, it was informed that a lawsuit was filed against the Company in Tel Aviv-Jaffa District Court
by minority shareholders of its subsidiary, Cannolam. The lawsuit was filed as part of a conflict between the shareholders and the Company,
which is related to disagreements concerning the ongoing management of Cannolam.
has conducted a preliminary review of the claims made by the minority shareholders, and believes that they lack a valid legal basis.
The Company is evaluating all legal options, including potential counterclaims. The Company is committed to vigorously defending its
interests and will take all legal actions available to it.
InterCure (dba Canndoc)
(dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North
America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to
offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market
leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale"
model to lead the fastest growing cannabis global market outside of North America.
more information, visit: http://www.intercure.co.
press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating
to the outcomes of the noted lawsuit. These statements are often characterized by terminology such as "believes," "hopes,"
"may," "anticipates," "should," "intends," "plans," "will," "expects,"
"estimates," "projects," "positioned," "strategy" and similar expressions and are based
on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate.. Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such
statements. Many factors could cause InterCure's actual activities or results to differ materially from the activities and results
anticipated in forward-looking statements. Forward-looking information is based on a number of assumptions and is subject to a number
of risks and uncertainties, many of which are beyond InterCure's control, which could cause actual results and events to differ
materially from those that are disclosed in or implied by such forward-looking information. InterCure undertakes no obligation to update
such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by
Cohen, Chief Financial Officer

Frequently Asked Questions

What lawsuit was filed against InterCure Ltd.?

Minority shareholders of Cannolam filed a lawsuit against InterCure.

Where was the lawsuit against InterCure filed?

The lawsuit was filed in the Tel Aviv-Jaffa District Court.

What are the shareholders disputing in the lawsuit?

The dispute concerns ongoing management issues of Cannolam.

How does InterCure plan to respond to the lawsuit?

InterCure intends to vigorously defend its interests and explore counterclaims.

What does InterCure specialize in?

InterCure is a leading medical cannabis company outside North America.

Last updated: Apr 25, 2023